Lymfom kliniske forsøg i Tennessee
15 studier for Lymfom søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Sarah Cannon Research Institute Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 1/2
Op til 25 år · Alle køn · Opdateret 25. sep. 2026 · NCT04094610A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Saint Jude Children's Research Hospital, Memphis
RekruttererFase 1/2
12 Months – 21 Years · Alle køn · Opdateret 11. sep. 2026 · NCT04870944TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07082803Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 23. jan. 2026 · NCT06326463cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
RekruttererObservationsstudie
Alder 12 til 80 · Alle køn · Opdateret 28. aug. 2025 · NCT07145411Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.